Compare GSK plc (GSK) vs US Global Jets ETF (JETS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs US Global Jets ETF — how do they compare? GSK plc trades at $46.62 (market cap $91.88B), while US Global Jets ETF trades at $27.29 (market cap $878.48M). The key difference: GSK plc is far larger — about 104.6× US Global Jets ETF's market cap, and GSK plc pays a 3.9% dividend while US Global Jets ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and US Global Jets ETF for 26 Days on average.
| GSK | JETS | |
|---|---|---|
Market Cap | $91.88B | $878.48M |
Volume | 7,730,529 | 4,465,925 |
Sector | Health | Sector/Thematic |
52-Week High | $61.18 | $33.53 |
52-Week Low | $43.24 | $23.64 |
Typical Hold Time | 93 Days | 26 Days |
Enterprise Value | $111.88B | — |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.45, down 1.21% with bearish technical signals. The company shows strong fundamentals with revenue growth to $32.67B in 2025 and consistent earnings beats. Valuation metrics appear reasonable with P/E of 14.89 and EV/EBITDA of 8.75. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite near-term technical weakness.
GSK presents a mixed outlook with strong profitability and pipeline expansion offset by technical bearishness and HIV patent concerns. The company's 29.73% ROE and recent earnings outperformance support investment appeal, while the bearish moving average signal and competitive pressures warrant caution. Analyst consensus leans hold with 55% neutral rating, suggesting balanced risk-reward for long-term investors.
JETS ETF trades at $27.29, down 1.37% amid bearish technical signals with 17 sell indicators versus 4 buy signals. The airline-focused ETF faces headwinds from rising fuel costs and geopolitical tensions, while technical analysis shows strong resistance at $28 and support at $27. Recent news highlights underperformance compared to defense-focused aerospace ETFs and pressure from Middle East conflicts driving up airline operating expenses.
The outlook remains challenging with fuel cost volatility and competitive pressure from alternative aerospace investments. While travel demand provides some support, the ETF's concentration on airline operators exposes investors to cyclical industry risks and margin compression from elevated fuel expenses. Near-term performance depends on fuel price stabilization and geopolitical developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About US Global Jets ETF
JETS provides targeted exposure to the global airline industry, including commercial airlines, aircraft manufacturers, and airport operators. It focuses on major U.S. and international carriers like Delta, United, and American Airlines.
Read more on JETS →
